These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 28042949)

  • 21. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial.
    Geletneky K; Hajda J; Angelova AL; Leuchs B; Capper D; Bartsch AJ; Neumann JO; Schöning T; Hüsing J; Beelte B; Kiprianova I; Roscher M; Bhat R; von Deimling A; Brück W; Just A; Frehtman V; Löbhard S; Terletskaia-Ladwig E; Fry J; Jochims K; Daniel V; Krebs O; Dahm M; Huber B; Unterberg A; Rommelaere J
    Mol Ther; 2017 Dec; 25(12):2620-2634. PubMed ID: 28967558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CXC-chemokine-ligand-10 gene therapy efficiently inhibits the growth of cervical carcinoma on the basis of its anti-angiogenic and antiviral activity.
    Wang LL; Chen P; Luo S; Li J; Liu K; Hu HZ; Wei YQ
    Biotechnol Appl Biochem; 2009 Jul; 53(3):209-16. PubMed ID: 19257857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncolytic parvovirus H1 induces release of heat-shock protein HSP72 in susceptible human tumor cells but may not affect primary immune cells.
    Moehler M; Zeidler M; Schede J; Rommelaere J; Galle PR; Cornelis JJ; Heike M
    Cancer Gene Ther; 2003 Jun; 10(6):477-80. PubMed ID: 12768193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis.
    Basset L; Chevalier S; Danger Y; Arshad MI; Piquet-Pellorce C; Gascan H; Samson M
    J Mol Med (Berl); 2015 Dec; 93(12):1355-67. PubMed ID: 26199110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CXCL4 and CXCL4L1 Differentially Affect Monocyte Survival and Dendritic Cell Differentiation and Phagocytosis.
    Gouwy M; Ruytinx P; Radice E; Claudi F; Van Raemdonck K; Bonecchi R; Locati M; Struyf S
    PLoS One; 2016; 11(11):e0166006. PubMed ID: 27828999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer.
    Grekova SP; Aprahamian M; Daeffler L; Leuchs B; Angelova A; Giese T; Galabov A; Heller A; Giese NA; Rommelaere J; Raykov Z
    Cancer Biol Ther; 2011 Nov; 12(10):888-95. PubMed ID: 22024742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of angiogenesis-driven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine.
    Albini A; Morini M; D'Agostini F; Ferrari N; Campelli F; Arena G; Noonan DM; Pesce C; De Flora S
    Cancer Res; 2001 Nov; 61(22):8171-8. PubMed ID: 11719447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer.
    Angelova AL; Grekova SP; Heller A; Kuhlmann O; Soyka E; Giese T; Aprahamian M; Bour G; Rüffer S; Cziepluch C; Daeffler L; Rommelaere J; Werner J; Raykov Z; Giese NA
    J Virol; 2014 May; 88(10):5263-76. PubMed ID: 24574398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncolytic murine autonomous parvovirus, a candidate vector for glioma gene therapy, is innocuous to normal and immunocompetent mouse glial cells.
    Abschuetz A; Kehl T; Geibig R; Leuchs B; Rommelaere J; Régnier-Vigouroux A
    Cell Tissue Res; 2006 Sep; 325(3):423-36. PubMed ID: 16699801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of p38(MAPK) mediates the angiostatic effect of the chemokine receptor CXCR3-B.
    Petrai I; Rombouts K; Lasagni L; Annunziato F; Cosmi L; Romanelli RG; Sagrinati C; Mazzinghi B; Pinzani M; Romagnani S; Romagnani P; Marra F
    Int J Biochem Cell Biol; 2008; 40(9):1764-74. PubMed ID: 18291705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model.
    Raykov Z; Grekova S; Galabov AS; Balboni G; Koch U; Aprahamian M; Rommelaere J
    Oncol Rep; 2007 Jun; 17(6):1493-9. PubMed ID: 17487410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parvovirus vectors for cancer gene therapy.
    Ponnazhagan S
    Expert Opin Biol Ther; 2004 Jan; 4(1):53-64. PubMed ID: 14680468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural Properties of CXCL4L1 and Its Recognition of the CXCR3 N-Terminus.
    Liu YH; Chuang CH; Lee YZ; Lee ET; Lo CL; Wu CY; Huang LK; Bikfalvi A; Sue SC
    Biochemistry; 2023 Feb; 62(3):722-734. PubMed ID: 36626574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CXCR3 ligands in disease and therapy.
    Van Raemdonck K; Van den Steen PE; Liekens S; Van Damme J; Struyf S
    Cytokine Growth Factor Rev; 2015 Jun; 26(3):311-27. PubMed ID: 25498524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.
    Lasagni L; Francalanci M; Annunziato F; Lazzeri E; Giannini S; Cosmi L; Sagrinati C; Mazzinghi B; Orlando C; Maggi E; Marra F; Romagnani S; Serio M; Romagnani P
    J Exp Med; 2003 Jun; 197(11):1537-49. PubMed ID: 12782716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of angiostatic platelet factor-4var/CXCL4L1 counterbalances angiogenic impulses of vascular endothelial growth factor, interleukin-8/CXCL8, and stromal cell-derived factor 1/CXCL12 in esophageal and colorectal cancer.
    Verbeke H; De Hertogh G; Li S; Vandercappellen J; Noppen S; Schutyser E; El-Asrar AA; Opdenakker G; Van Damme J; Geboes K; Struyf S
    Hum Pathol; 2010 Jul; 41(7):990-1001. PubMed ID: 20334899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid.
    Allaume X; El-Andaloussi N; Leuchs B; Bonifati S; Kulkarni A; Marttila T; Kaufmann JK; Nettelbeck DM; Kleinschmidt J; Rommelaere J; Marchini A
    J Virol; 2012 Apr; 86(7):3452-65. PubMed ID: 22258256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS.
    Ensoli B; Markham P; Kao V; Barillari G; Fiorelli V; Gendelman R; Raffeld M; Zon G; Gallo RC
    J Clin Invest; 1994 Nov; 94(5):1736-46. PubMed ID: 7525646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells.
    Zipin-Roitman A; Meshel T; Sagi-Assif O; Shalmon B; Avivi C; Pfeffer RM; Witz IP; Ben-Baruch A
    Cancer Res; 2007 Apr; 67(7):3396-405. PubMed ID: 17409450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma.
    Sgadari C; Barillari G; Toschi E; Carlei D; Bacigalupo I; Baccarini S; Palladino C; Leone P; Bugarini R; Malavasi L; Cafaro A; Falchi M; Valdembri D; Rezza G; Bussolino F; Monini P; Ensoli B
    Nat Med; 2002 Mar; 8(3):225-32. PubMed ID: 11875492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.